A Phase 3 interventional study of NBI-1065845 and Placebo in Major Depressive Disorder, sponsored by Neurocrine Biosciences. Recruiting at 60 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-24.
Sponsored by Neurocrine Biosciences · Phase 3, Interventional, and Treatment
The primary objective of this study is to evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in participants with MDD.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined Inclusion and Exclusion criteria may apply.
Participants will be treated with NBI-1065845 during the open-label treatment period.
Drug: NBI-1065845
Participants will be randomized to receive NBI-1065845 during the randomized double-blind maintenance period.
Drug: NBI-1065845
Participants will be randomized to receive matching placebo during the randomized double-blind maintenance period.
Drug: Placebo
Oral tablet
Oral tablet
Time from Randomization to Relapse
Time frame: From randomization to the earliest of relapse or end-of study (up to approximately 32 months)
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neurocrine Biosciences